Neumora Therapeutics (NMRA) Common Equity (2022 - 2026)

Neumora Therapeutics has reported Common Equity for 5 years, with the latest figure at $70.7 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 69.05% year-over-year to $70.7 million; the trailing twelve-month figure through Mar 2026 stood at $70.7 million (down 69.05% YoY), and the FY2025 full-year result was $103.9 million, down 63.82% from the prior year.
• Common Equity for Q1 2026 stood at $70.7 million, down from $103.9 million in the prior quarter.
• The five-year high for Common Equity was $512.7 million in Q3 2023, with the low at -$513.5 million in Q2 2023.
• Average Common Equity over 5 years is $83.5 million, with a median of $182.9 million recorded in 2025.
• Year-over-year, Common Equity jumped 221.49% in 2023 and sank 69.05% in 2026.
• Tracing NMRA's Common Equity over 5 years: stood at -$446.8 million in 2022, then soared by 204.97% to $469.1 million in 2023, then slumped by 38.8% to $287.1 million in 2024, then sank by 63.82% to $103.9 million in 2025, then slumped by 31.95% to $70.7 million in 2026.
• The last three Common Equity figures came in at $70.7 million (Q1 2026), $103.9 million (Q4 2025), and $132.2 million (Q3 2025), per Business Quant data.

Peer Comparison